Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy
Julia M. L. Brotherton A B H , John M. Kaldor C and Suzanne M. Garland D E F GA Victorian Cytology Service, PO Box 310, East Melbourne, Vic. 8002, Australia.
B National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead, Discipline of Paediatrics and Child Health, School of Public Health, University of Sydney, Sydney, NSW 2006, Australia.
C National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia.
D Clinical Microbiology and Infectious Diseases, Royal Women’s Hospital, Melbourne, Vic 3052, Australia.
E Department of Clinical Microbiology, Royal Children’s Hospital, Melbourne, Vic. 3052, Australia.
F Faculty of Medicine, Dentistry and Health, Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Vic. 3053, Australia.
G Murdoch Children’s Research Institute, University of Melbourne, Melbourne, Vic. 3052, Australia.
H Corresponding author. Email: jbrother@vcs.org.au
Sexual Health 7(3) 310-319 https://doi.org/10.1071/SH09137
Submitted: 2 December 2009 Accepted: 13 April 2010 Published: 19 August 2010
Abstract
This paper describes a possible multifaceted approach to human papillomavirus (HPV) related surveillance in Australia following implementation of a national HPV vaccination program. We describe eight main components: monitoring of vaccine coverage, vaccine safety, type-specific HPV infection surveillance, cervical cytology (Pap screening) coverage and screen detected lesion prevalence, cervical cancer incidence and mortality, genital wart incidence, incidence of recurrent respiratory papillomatosis, and knowledge, attitudes and beliefs about HPV and HPV vaccination. Australia is well placed to monitor the impact of its HPV vaccination program as well as to measure vaccine effectiveness with existing HPV vaccines, cervical screening and cancer registries.
Additional keywords: cervical cancer, genital warts, Pap smears, recurrent respiratory papillomatosis, vaccination, vaccine safety.
Acknowledgements
We would like to acknowledge the intellectual contribution to the ideas contained in this paper made by the following individuals, with whom we have discussed many of the issues in this paper: Dr Rosemary Lester, Dr Shelley Deeks, Dr Bronwen Harvey, Dr Vicki Krause, Professor Peter McIntyre, Associate Professor Marion Saville, Dr Christine Selvey and Dr Rosalind Webby.
[1] Leask J, Jackson C, Trevena L, McCaffery K, Brotherton J. Implementation of the Australian HPV vaccination program for adult women: qualitative key informant interviews. Vaccine 2009; 27 5505–12.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[2] Garland SM, Brotherton JML, Skinner SR, Pitts M, Saville M, Mola G, et al. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention. Vaccine 2008; 26 M80–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[3]
[4] Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010;
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[5] CDC Updated guidelines for evaluating public health surveillance systems. MMWR Recomm Rep 2001; 50 1–35.
[6] World Health Organization Human papillomavirus vaccines WHO position paper. Wkly Epidemiol Rec 2009; 84 118–31.
| PubMed |
[7] Siegrist C, Lewis E, Eskola J, Evans S, Black S. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26 979–84.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[8] Heley S, Brotherton J. I’ve had the HPV vaccine: why is my Pap test abnormal? Aust Fam Physician 2009; 38 977–9.
| PubMed |
[9]
[10] Wilkinson DE, Baylis SA, Padley D, Heath AB, Ferguson M, et al. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer 2010; 126 2969–83.
| PubMed |
[11] Canfell K. Models of cervical screening in the era of HPV vaccination. Sex Health 2010; 7 359–67.
| Crossref | GoogleScholarGoogle Scholar |
[12] Regan DG, Philp DP, Waters EK. Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective. Sex Health 2010; 7 368–75.
| Crossref | GoogleScholarGoogle Scholar |
[13] Gertig D, Brotherton J, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2010;
| Crossref | GoogleScholarGoogle Scholar |
[14]
[15] Duclos P. A global perspective on vaccine safety. Vaccine 2004; 22 2059–63.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[16] Lawrence G. National Vaccine Safety Workshop: summary and draft recommendations. Commun Dis Intell 2006; 30 378–80.
| PubMed |
[17] Gold M, Buttery J, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health 2010; 7 320–4.
| Crossref | GoogleScholarGoogle Scholar |
[18] Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 2008; 32 371–87.
| PubMed |
[19]
[20] Stevens M, Tabrizi S, Quinn M, Garland S. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Cancer 2006; 16 1017–24.
| Crossref | GoogleScholarGoogle Scholar |
[21] Brestavoc B, Harnett G, Smith D, Frost F, Shellam G. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. J Med Virol 2005; 76 106–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[22] Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol Surv 2009; 64 306–8.
| Crossref | GoogleScholarGoogle Scholar |
[23] Mitchell H, Hocking J. Influences on the risk of recurrent high grade cervical abnormality. Int J Gynecol Cancer 2002; 12 728–34.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[24] Brotherton JML. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008; 26 250–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[25] Clifford G, Smith J, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89 101–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[26] Clifford G, Rana R, Franceschi S, Smith J, Gough G, Pimenta J. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14 1157–64.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[27]
[28] Budd A, Sturrock A. Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination. Sex Health 2010; 7 328–34.
| Crossref | GoogleScholarGoogle Scholar |
[29] Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. J Infect Dis 2009; 119 1–10.
[30] Garland S, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356 1928–43.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[31] Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85 499–502.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[32] Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008; 118 1236–47.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[33] Rosenthal DA, Dyson S, Pitts M, Garland SM. Challenges to accepting a human papillomavirus (HPV) vaccine: a qualitative study of Australian women. Women’s Health 2007; 45 59–73.
| Crossref | GoogleScholarGoogle Scholar |
[34] Pitts MK, Dyson SJ, Rosenthal DA, Garland SM. Knowledge and awareness of human papillomavirus (HPV): attitudes towards HPV vaccination among a representative sample of women in Victoria, Australia. Sex Health 2007; 4 177–80.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[35] Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45 107–14.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[36] Cooper Robbins SC, Bernard D, McCaffery K, Brotherton J, Garland S, Skinner SR. “Is cancer contagious?” Australian adolescent girls and their parents: making the most of limited information about HPV and HPV vaccination. Vaccine 2010; 28 3398–408.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[37] Donovan B, Fairley C. What can surveillance of genital warts tell us? Sex Health 2010; 7 325–7.
| Crossref | GoogleScholarGoogle Scholar |
[38] Novakovic D, Cheng ATL, Cope DH, Brotherton JML. Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study. Sex Health 2010; 7 253–61.
| Crossref | GoogleScholarGoogle Scholar |
